QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 brainstorm-cell-therapeutics-reaches-alignment-with-fda-on-chemistry-manufacturing-and-control-aspects-of-phase-3b-nurown-clinical-trial-for-amyotrophic-lateral-sclerosis

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative dise...

 brainstorm-cell-therapeutics-taps-haro-hartounian-phd-as-coo-effective-june-18

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative dise...

 brainstorm-cell-therapeutics-to-present-new-biomarker-data-suggesting-als-patients-may-benefit-from-longer-term-treatment-with-nurown

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative dise...

 brainstorm-cell-q1-2024-adj-eps-005-beats-007-estimate

Brainstorm Cell (NASDAQ:BCLI) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.0...

 brainstorm-cell-therapeutics-received-letter-from-nasdaq-indicating-co-had-not-regained-compliance-with-minimum-bid-price-requirement-by-april-29

- SEC Filing

 reported-earlier-brainstorm-cell-therapeutics-announces-management-changes-as-it-plans-registrational-phase-3b-trial-of-nurown

Bob Dagher, MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of D...

 brainstorm-cell-therapeutics-regains-compliance-with-nasdaq-minimum-market-value-rule

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI, ", , the Company", , )))), a leading developer of cellular therapies fo...

 why-biophytis-shares-are-trading-higher-by-around-55-here-are-20-stocks-moving-premarket

Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results.

 brainstorm-cell-q4-eps-011-beats-015-estimate

Brainstorm Cell (NASDAQ:BCLI) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.1...